Search

Your search keyword '"Takano, Masashi"' showing total 7 results
Start Over Author "Takano, Masashi" Journal cancer chemotherapy and pharmacology
7 results on '"Takano, Masashi"'

7. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.

Author

Miyamoto M, Takano M, Kuwahara M, Soyama H, Kato K, Matuura H, Sakamoto T, Takasaki K, Aoyama T, Yoshikawa T, and Furuya K

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dose-Response Relationship, Drug, Endometrial Neoplasms genetics, Female, Genotype, Humans, Irinotecan adverse effects, Middle Aged, Organoplatinum Compounds adverse effects, Remission Induction, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Endometrial Neoplasms drug therapy, Glucuronosyltransferase genetics, Irinotecan administration & dosage, Neoplasm Recurrence, Local drug therapy, Organoplatinum Compounds administration & dosage
Abstract

Purpose: We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype., Methods: Between 2009 and 2017, 21 patients who received CPT-N therapy for recurrent endometrial carcinoma as second- or third-line chemotherapy at our hospital were identified. The CPT-N regimen included 40-70 mg/m 2 of CPT-11 on days 1, 8, and 15, and 50 mg/m 2 of nedaplatin on day 1, q4 weeks., Results: The median patient age was 63 years. The number of prior chemotherapeutic regimens ranged from 1 to 2. Two patients had prior pelvic irradiation. The response rate [ratio of complete remission (CR) to partial remission (PR)] of CPT-N therapy was 3 of 21 (14.3%), and clinical benefit rate (CBR) [the combined percentages of CR, PR, and stable disease (SD)] was 9 of 21 (42.8%). Toxicities included grade 3 neutropenia [4 (19.0%) cases], grade 3 febrile neutropenia [2 (9.5%) cases], and grade 3 diarrhea [3 (14.3%) cases]; all resolved with conservative treatment. Patients with a wild-type UGT1A1 status received higher doses of CPT-11 (p = 0.048) and had similar RR and CBR compared to those with a UGT1A1*6 and *28 status. There were no significant differences in frequencies of hematological or non-hematological toxicities, regardless of UGT1A1 status., Conclusions: The CPT-N regimen for recurrent and refractory endometrial carcinoma had tolerable side effects and significant efficacy. This regimen is a viable treatment option for endometrial carcinoma.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results